| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two … PE Sax, D Wohl, MT Yin, F Post, E DeJesus, M Saag, A Pozniak, ... The Lancet 385 (9987), 2606-2615, 2015 | 736* | 2015 |
| Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority … P Cahn, AL Pozniak, H Mingrone, A Shuldyakov, C Brites, ... The Lancet 382 (9893), 700-708, 2013 | 598 | 2013 |
| Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 R Ortiz, E DeJesus, H Khanlou, E Voronin, J van Lunzen, ... Aids 22 (12), 1389-1397, 2008 | 535 | 2008 |
| Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1 … JM Molina, J Andrade-Villanueva, J Echevarria, P Chetchotisakd, J Corral, ... The Lancet 372 (9639), 646-655, 2008 | 531 | 2008 |
| Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3 … CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie, MA Johnson, ... The Lancet 378 (9787), 229-237, 2011 | 466 | 2011 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 400 | 2019 |
| Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression S Swindells, JF Andrade-Villanueva, GJ Richmond, G Rizzardini, ... New England Journal of Medicine 382 (12), 1112-1123, 2020 | 389 | 2020 |
| The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study FR Machado, AB Cavalcanti, FA Bozza, EM Ferreira, FSA Carrara, ... The Lancet Infectious Diseases 17 (11), 1180-1189, 2017 | 375 | 2017 |
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active … A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ... The Lancet Infectious Diseases 16 (1), 43-52, 2016 | 365 | 2016 |
| Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV … JM Molina, J Andrade-Villanueva, J Echevarria, P Chetchotisakd, J Corral, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 53 (3), 323-332, 2010 | 360 | 2010 |
| Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2 … JJ Eron, B Young, DA Cooper, M Youle, E DeJesus, ... The Lancet 375 (9712), 396-407, 2010 | 355 | 2010 |
| Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non … ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, ... The Lancet 396 (10267), 1994-2005, 2020 | 242 | 2020 |
| Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial JB Cohen, TC Hanff, P William, N Sweitzer, NR Rosado-Santander, ... The lancet respiratory medicine 9 (3), 275-284, 2021 | 232 | 2021 |
| Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, ... The Lancet infectious diseases 11 (12), 907-915, 2011 | 228 | 2011 |
| Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in … P Cahn, J Andrade-Villanueva, JR Arribas, JM Gatell, JR Lama, M Norton, ... The Lancet Infectious Diseases 14 (7), 572-580, 2014 | 206 | 2014 |
| Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor … JM Molina, A LaMarca, J Andrade-Villanueva, B Clotet, N Clumeck, ... The Lancet infectious diseases 12 (1), 27-35, 2012 | 206 | 2012 |
| Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1–infected patients: week 48 results JE Gallant, E Koenig, J Andrade-Villanueva, P Chetchotisakd, E DeJesus, ... The Journal of infectious diseases 208 (1), 32-39, 2013 | 167 | 2013 |
| Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated … C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ... The Lancet HIV 4 (12), e536-e546, 2017 | 137 | 2017 |
| Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial ARTEN investigators, V Soriano, K Arastéh, H Migrone, T Lutz, M Opravil, ... Antiviral therapy 16 (3), 339-348, 2011 | 125 | 2011 |
| Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials G Rizzardini, ET Overton, C Orkin, S Swindells, K Arasteh, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 85 (4), 498-506, 2020 | 115 | 2020 |
